CYP2C19 Genetic Polymorphisms in Children and Young Adults with Cancer: A Cross-sectional Study
| Author | Ali Amanati | en |
| Author | Hadis Jafarian | en |
| Author | Seyed Reza Abdipour Mehrian | en |
| Author | Sarvin Sajedianfard | en |
| Author | Parisa Badiee | en |
| Author | Fatemeh Ghasemi | en |
| Author | Farima Safari | en |
| Author | Armina Farkarian | en |
| Orcid | Ali Amanati [0000-0001-9173-2853] | en |
| Orcid | Hadis Jafarian [0000-0002-8959-6482] | en |
| Orcid | Seyed Reza Abdipour Mehrian [0000-0002-4447-4131] | en |
| Orcid | Parisa Badiee [0000-0003-4221-2995] | en |
| Orcid | Fatemeh Ghasemi [0000-0001-5587-4336] | en |
| Issued Date | 2026-04-30 | en |
| Abstract | Background: Inter-individual variation in drug response has long been a concern in the treatment of patients, particularly those with immunosuppressed states who are receiving voriconazole for fungal infections. Objectives: This study aimed to investigate the predominance of genetic polymorphisms in pediatric patients and young adults with malignancies. Methods: This cross-sectional study was conducted between February 2022 and March 2023. Blood samples were collected from patients before the administration of anticancer drugs. Genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Demographic data and patients’ outcomes were collected from the electronic medical record information system. Chi-square or Fisher’s exact test was applied to assess relations between genotypes and clinical variables. Results: Of the 78 patients enrolled in the study, 74 patients were evaluated for CYP2C19 genotyping. The most common underlying disease was acute lymphoblastic leukemia. Fifty-one percent of the patients were homozygous for the wild type (CYP2C19*1 allele). The frequency of CYP2C19*17 and CYP2C19*3 alleles were 16.2% (12/74) and 1.3% (1/74), respectively. No significant relationship between the type of cancer or patient’s outcome and CYP2C19 tested genotypes was observed. The CYP2C19*17 allele was the predominant allele among the studied patients. Conclusions: The CYP2C19*17 allele was notably prevalent among the patients studied, which may result in rapid (heterozygous genotype) or ultra-rapid (homozygous genotype) metabolizer phenotypes, leading to subtherapeutic drug levels in clinical settings. | en |
| DOI | https://doi.org/10.5812/apid-162809 | en |
| Keyword | CYP2C19 | en |
| Keyword | Genotype | en |
| Keyword | Pediatrics | en |
| Keyword | Cancer | en |
| Publisher | Brieflands | en |
| Title | CYP2C19 Genetic Polymorphisms in Children and Young Adults with Cancer: A Cross-sectional Study | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- apid-14-2-162809-publish-pdf.pdf
- Size:
- 376.83 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF